Medical Scientists Inc Releases MediSave 3.0

Medical Scientists Inc announced the release of its next-generation MediSave 3.0 software suite for forecasting the disease-specific medical costs of Asthma, Diabetes, and Coronary Artery Disease. MediSave 3.0 is the company's latest addition to its complete line of healthcare predictive modeling technologies. The company has seen sales more than triple since the release of the new platform (MediSave 2.0) last year.

The new MediSave 3.0 software has already been licensed by many of the nation's leading health plans, insurers, PBMs, disease management companies, and Fortune 500 employers, including Pitney Bowes, Wausau Benefits, Blue Cross Blue Shield of Minnesota, Medica Health Plans (of Allina Health System), CorSolutions Medical, and Advance PCS. The model has quickly become a favorite for predicting future medical costs, forecasting the impact of disease management, and identifying the disease-related cost of lost work days. This is largely due to the model's unprecedented accuracy, scalability and versatility. MediSave has been shown in recent validation studies to forecast future costs within 5% of reported claims.

The model will assess the current and future burden of illness for Diabetes, Asthma and CAD, which represent among the most expensive, yet treatable, drivers of healthcare costs for corporations, insurers and health plans today. The impact these diseases have upon healthcare costs has been evidenced in the recent boom in the healthcare "disease management" field. The model's ability to analyze and forecast the impact of various disease management strategies has certainly contributed to its rapid growth. The new software will allow licensing organizations to select and analyze the diseases or conditions that will most directly impact their specific populations. Gregory P. Gilmet, MD, MPH, vice president and Medical Director for Medica Health Plans, a MediSave customer, states "With MediSave, I believe Medical Scientists has developed a truly unique tool with the capacity to provide us with some real answers on how to improve care, and manage costs. Furthermore, the scalable nature of the model allows us the opportunity to speak to our customers in non-generic terms, and provide them with real insight into their current burden of illness."

The new MediSave 3.0 software also comes preloaded with a special Triangulated database for its CAD, Diabetes and Asthma modules. MediSave's proprietary Triangulated database is what gives it the unique ability to accurately forecast future medical costs for a population, even without a detailed claims history. The database is comprised of 3 separate data sources, including a comprehensive national claims database of over 7.2 million covered lives, an extensive meta-analysis of the literature, and pivotal expert opinion. By using this proprietary algorithm, Medical Scientists is able to utilize normative data that offers its users the most accurate and relevant data possible, which can be used when population-specific claims data may not be readily available.

Medical Scientists, www.medicalscientists.com, Inc is a privately held healthcare company funded by venture capital. The company is a leading provider of information technology and consulting services to the healthcare industry, specializing in predictive modeling, risk profiling, and clinical actuarial decision-support. The MediSave software suite predicts the disease-specific medical costs of a specific population, and the impact of potential intervention. HybridAI is Rational Artificial Intelligence (RAI) technology that predicts catastrophic risk (i.e. identify low cost members will soon become high cost) for organizations at risk. HybridAI offers unprecedented levels of speed and accuracy, delivering predictions in 1/10th the time of traditional systems, and up to 99% accuracy. HealthChek models assess disease-specific health risks of an individual, and recommend steps for improvement.

Contact Jeffrey M. Nicholson, Product Manager Medical Scientists Inc, 195 State Street, Suite 5000, Boston MA 02109, 617-723-7710 x304, jnicholson@medicalscientists.com.